Results of the Phase 3 AETHERA Trial of Brentuximab Vedotin for Patients with HL at Risk for Progression After Autologous Stem Cell Transplant


Results of the Phase 3 AETHERA Trial of Brentuximab Vedotin for Patients with HL at Risk for Progression After Autologous Stem Cell Transplant
Slides from a presentation at ASH 2014 and transcribed comments from a recent interview with Craig Moskowitz, MD (1/6/15)
Moskowitz CH et al. The AETHERA trial: Results of a randomized, double-blind, placebo-controlled Phase 3 study of brentuximab vedotin in the treatment of patients at risk of Hodgkin lymphoma progression following autologous stem cell transplant. Proc ASH 2014;Abstract 673.

Dr Moskowitz is Clinical Director of the Division of Hematologic Oncology, Attending Physician for Lymphoma and Adult BMT Services, Member of Memorial Sloan Kettering Cancer Center and Professor of Medicine at the Weill Medical College of Cornell University in New York, New York.